Risk factors for catheter‐related thrombosis (CRT) in cancer patients: a patient‐level data (IPD) meta‐analysis of clinical trials and prospective studies
暂无分享,去创建一个
C. Cimminiello | M. Moia | G. Agnelli | M. Huisman | C. J. van Rooden | T. Moua | W. Saber | S. Povoski | A. Young | E. Williams | R. Biffi | A. Lee | S. Malak | D. Fagnani | S. Couban | M. Magagnoli | M. Verso | M. De Cicco
[1] U. Hoffmann,et al. [Upper extremity deep venous thrombosis]. , 2012, Deutsche medizinische Wochenschrift.
[2] F. Bourgeois,et al. Peripherally Inserted Central Catheters , 2011, Pediatric emergency care.
[3] M. De Cicco,et al. Early and short-term acenocumarine or dalteparin for the prevention of central vein catheter-related thrombosis in cancer patients: a randomized controlled study based on serial venographies. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] A. Khorana,et al. Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] Clifford W Colwell,et al. Prevention of Venous Thromboembolism* American College of Chest Physicians Evidence- Based Clinical Practice Guidelines (8th Edition) , 2008 .
[6] B. Barlogie,et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma , 2008, Leukemia.
[7] C. Freytes. Thromboembolic complications related to central venous access catheters in cancer patients. , 2007, Seminars in thrombosis and hemostasis.
[8] C. Porta,et al. Thrombosis-related complications and mortality in cancer patients with central venous devices: an observational study on the effect of antithrombotic prophylaxis. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] M. De Cicco,et al. Short-term acenocumarine (A) or dalteparine (D) for the prevention of central venous catheter-related thrombosis (CVCrT) in cancer patients. A randomized controlled study based on serial venographies. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] M. Levine,et al. Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] G. Steger,et al. Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] L. Castagna,et al. High incidence of INR alteration in gastrointestinal cancer patients treated with mini-dose warfarin and 5-fluorouracil-based regimens. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] T. Othman,et al. Prevalence of inherited prothrombotic abnormalities and central venous catheter-related thrombosis in haematopoietic stem cell transplants recipients , 2005, Bone Marrow Transplantation.
[14] D. Anderson,et al. Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Armando Santoro,et al. Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] D. Kerr,et al. WARP - A multicentre prospective randomised controlled trial (RCT) of thrombosis prophylaxis with warfarin in cancer patients with central venous catheters (CVCs) , 2005 .
[17] T. Barbui,et al. Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective multicentre study , 2005, British journal of haematology.
[18] R. Rosovsky,et al. Catheter-related thrombosis in cancer patients: pathophysiology, diagnosis, and management. , 2005, Hematology/oncology clinics of North America.
[19] S. Povoski. Long-term venous access , 2005 .
[20] G. Severi,et al. Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] F. Rosendaal,et al. The contribution of factor V Leiden and prothrombin G20210A mutation to the risk of central venous catheter-related thrombosis. , 2004, Haematologica.
[22] Michael K Gould,et al. Preventing complications of central venous catheterization. , 2003, The New England journal of medicine.
[23] G. Lambertenghi-Deliliers,et al. Central Venous Catheter-related Complications in Patients with Hematological Malignancies: A Retrospective Analysis of Risk Factors and Prophylactic Measures , 2003, Leukemia & lymphoma.
[24] S. Laporte,et al. Low-molecular-weight heparin (nadroparin) and very low doses of warfarin in the prevention of upper extremity thrombosis in cancer patients with indwelling long-term central venous catheters: a pilot randomized trial. , 2003, Haematologica.
[25] K. Sepkowitz,et al. Complication rates among cancer patients with peripherally inserted central catheters. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] B. Solomon,et al. Lack of efficacy of twice-weekly urokinase in the prevention of complications associated with Hickman catheters: a multicentre randomised comparison of urokinase versus heparin. , 2001, European journal of cancer.
[27] F. Orsi,et al. A randomized, prospective trial of central venous ports connected to standard open‐ended or Groshong catheters in adult oncology patients , 2001, Cancer.
[28] KyungMann Kim,et al. Central venous device‐related infection and thrombosis in patients treated with moderate dose continuous‐infusion interleukin‐2 , 2001, Cancer.
[29] J. Heit,et al. Prevention of venous thromboembolism. , 2001, Clinics in geriatric medicine.
[30] P. Massoure,et al. [Upper extremity deep venous thrombosis. 40 hospitalized patients]. , 2000, Journal des maladies vasculaires.
[31] S. Povoski. A Prospective Analysis of the Cephalic Vein Cutdown Approach for Chronic Indwelling Central Venous Access in 100 Consecutive Cancer Patients , 2000, Annals of Surgical Oncology.
[32] J. Todd. Peripherally inserted central catheters. , 1998, Professional nurse.
[33] P Prandoni,et al. Upper-extremity deep vein thrombosis. Risk factors, diagnosis, and complications. , 1997, Archives of internal medicine.
[34] R. Rosell,et al. Upper Extremity Deep Venous Thrombosis in Cancer Patients with Venous Access Devices - Prophylaxis with a Low Molecular Weight Heparin (Fragmin) , 1996, Thrombosis and Haemostasis.
[35] A R Jadad,et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.
[36] P. Benotti,et al. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. , 1990, Annals of internal medicine.
[37] E. Larson,et al. Hickman Catheter Infections in Patients With Malignancies , 1984, Medicine.
[38] J. Lokich,et al. Subclavian vein thrombosis in patients treated with infusion chemotherapy for advanced malignancy , 1983, Cancer.